BioWorld Asia

Sep. 19, 2007

NeuroSearch Shares Boosted By Tesofensine Obesity Data

Shares in NeuroSearch A/S gained almost 22 percent Monday on news that its candidate obesity drug tesofensine attained an average weight reduction of about 10 ten percent in a Phase IIb clinical trial. (BioWorld International) Read More

Ganymed Adds To Series C; Closes 37.2M Financing Round

No Abstract Read More

Gene Expression Levels Vary At Higher Levels Than Thought

Oxford BioMedica Using Sanofi Deal As Catalyst For Growth

European Industry Seeks Wider Links In Orphan Drug Programs

Other News To Note

Renovo Reports Positive Data From Phase IIb Trial Of Juvista

Mutabilis, Oroxcell Collaborate On Preclinical Antibiotic Agent

EU Commissioner Defends Rule Banning GM-Free Zones

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...